Last reviewed · How we verify

Kybella Flanks

Beer, Kenneth R., M.D., PA · FDA-approved active Small molecule

Kybella (deoxycholic acid) destroys fat cells through a naturally occurring bile acid that disrupts cell membranes, leading to permanent reduction of submental fat.

Kybella (deoxycholic acid) destroys fat cells through a naturally occurring bile acid that disrupts cell membranes, leading to permanent reduction of submental fat. Used for Reduction of submental fat (double chin) in adults.

At a glance

Generic nameKybella Flanks
SponsorBeer, Kenneth R., M.D., PA
Drug classLipid-dissolving agent
TargetAdipocyte cell membrane
ModalitySmall molecule
Therapeutic areaDermatology / Aesthetics
PhaseFDA-approved

Mechanism of action

Deoxycholic acid is a naturally occurring bile acid that, when injected into subcutaneous fat, causes adipocyte lysis and permanent destruction of fat cells. The body then metabolizes and eliminates the destroyed fat cells through normal physiological processes. This results in a permanent reduction of localized fat deposits in the treated area.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: